NCT05824052

Brief Summary

The objective of this study is to examine the effect of varying ozone doses on the levels of pro-inflammatory cytokines in synovial fluid collected from individuals with knee osteoarthritis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for not_applicable knee-osteoarthritis

Timeline
Completed

Started Apr 2023

Shorter than P25 for not_applicable knee-osteoarthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 8, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 21, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

April 21, 2023

Completed
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2023

Completed
4 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 24, 2023

Completed
Last Updated

May 25, 2023

Status Verified

May 1, 2023

Enrollment Period

29 days

First QC Date

April 8, 2023

Last Update Submit

May 24, 2023

Conditions

Keywords

Dose-dependent effectknee osteoarthritisozone therapypro-inflammatory cytokinessynovial fluid

Outcome Measures

Primary Outcomes (4)

  • Protein Determination

    The the total protein content in synovial fluid samples will be determined using a commercial kit based on the Bradford method (Coomassie Plus, Protein Assay, Thermofisher Scientific, Massachusetts, USA) and will be measured at 595 nm. A rapid and sensitive method will be used for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. The Bradford protein test will be based on the principle that when protein molecules bind to Coomassie dye under acidic conditions, the color will change from brown to blue.

    1 day

  • Measurement of Total Antioxidant Level (TAL)

    TAL refers to the measurement of the total antioxidant capacity of a substance. This capacity measures a substance's ability to prevent harm from free radicals and reactive oxygen species. Measuring the total antioxidant capacity can be done using different laboratory assays and can be affected by various factors, such as diet, lifestyle, and environment.TAL levels of the samples will be measured using commercially purchased kits according to the manufacturer's instructions (Rel Assay Diagnostics, Mega Tıp, Gaziantep, Turkey).

    1 day

  • Measurement of Total Oxidant Level (TOL)

    TOL refers to the total amount of oxidizing agents, such as ROS, in a substance or biological sample. Oxidative stress is caused by an imbalance between ROS production and antioxidant defense mechanisms, leading to cellular damage. Various lab assays, detecting biomarkers like MDA or protein carbonyls, can measure TOL, which can help diagnose and monitor diseases associated with oxidative stress, like cardiovascular disease and cancer. TOL levels of the samples will be measured using commercially purchased kits according to the manufacturer's instructions (Rel Assay Diagnostics, Mega Tıp, Gaziantep, Turkey).

    1 day

  • Oxidative Stress Index (OSI)

    OSI is a calculated value that assesses the balance between oxidative stress and antioxidant defense mechanisms in the body by dividing TOS by TAS. A higher OSI value indicates higher oxidative stress and lower antioxidant defense mechanisms. OSI measurement is helpful for diagnosing and monitoring diseases associated with oxidative stress like cardiovascular disease, diabetes, and cancer.

    1 day

Study Arms (3)

Group 1

NO INTERVENTION

The synovial fluid taken from the patients and not treated in any way.

Group 2

ACTIVE COMPARATOR

The synovial fluid taken from the patients and injected 10 gamma ozone.

Other: Ozone injection

Group 3

ACTIVE COMPARATOR

The synovial fluid taken from the patients and injected 30 gamma ozone.

Other: Ozone injection

Interventions

Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.

Group 2Group 3

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Being diagnosed with knee osteoarthritis.
  • Giving consent to participate in the study.

You may not qualify if:

  • \- Not giving consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sağlık Bilimleri Üniversitesi Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi

Istanbul, Kadıköy, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Ozone

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

OxygenGasesInorganic Chemicals

Study Officials

  • Emre Ata, M.D.

    Sultan Abdulhamid Han Training and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Synovial fluid samples taken from patients will be prepared to form 3 separate groups, one fluid will not be treated, one will be injected with 10 gamma and the other with 30 gamma ozone.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant

Study Record Dates

First Submitted

April 8, 2023

First Posted

April 21, 2023

Study Start

April 21, 2023

Primary Completion

May 20, 2023

Study Completion

May 24, 2023

Last Updated

May 25, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will share

Individual participant data (IPD) will be shared upon reasonable request by the principal investigator.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
1 year
Access Criteria
Individual participant data (IPD) will be shared upon reasonable request by the principal investigator.

Locations